Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Comment by Wino115on Feb 09, 2021 7:15pm
99 Views
Post# 32520381

RE:RE:RE:RE:RE:RE:RE:RE:TH is dead money

RE:RE:RE:RE:RE:RE:RE:RE:TH is dead money I sensed some of that in Levesque's original day 1 plan of review for 60/90 days, set realistic goals, hit them.  If not, reassess to get the right people and strategy in house. We saw that with Jovan for sales, now time to assess this further in finance and IR.  Let's hope they are not hungry for Cheetos...

ANALIAS00 wrote: All what some are trying to say is this:

- If your communication strategy is working but could be improved, you must admit that and improve asap. Do not auto-congradulate yourself. Be hungry.

- If you know that SP is undervaluated knowing time will prove it, you must not wait and act asap. Be hungry.

- If you succeed but you could have succeed faster, you can bring this up as a partial fail or partial win so you must not be totally satisfied. Be hungry.

- If you succeed but could have succeed even more, samething, you partially failed. Be hungry.

What I am trying to say is if you are taking bad decisions (strategy) during a match, you might still win the game. But bad decisions remains bad decisions and not trying to quickly improve will make you miss the playoff.

Samething with poker. Making bad decisions may still make you win sometime, but long term you will loose money.

TH's SP should be higher (not 14, not 10 but certainly $5 if you compare to other comparable biotech. TH seem to agree and if they do not take big part of the blame, I should be worry. But I think they do know and lets see what kind of improvement they come up with in the next couple of months.

jfm1330 wrote: That being said, I am totally in favor of improving the website and making more info easily available, like scientific papers, archiving webcasts of presentations, etc...

My point is that I just don't think it will make the difference on the stock price. Most small investors in thechnology stocks rely on percieved credibility and odds of success. It comes from outside validation and momentum building, and most importantly, hard facts. If Thera is to be successful there will be a trigger point for that. It happened on the Trogarzo story, and before that the Egrifta story, but both ended in disapointment. So skepticism will prevail until they can come up with more than hope.


jfm1330 wrote: There is enough on Thera's website to know what the company is doing and to understand the general principles behind their clinical programs. Sorry, but if you don't have the proper scientific background, more advanced scientific explainations won't be understandable. I don't want to look more intelligent than anybody by saying that, it is just a matter of mastering enough pertinent scientific principles, and if you do, you can do your own litterature review to further understand what they are doing and where it stands in the larger context, including possible competition, odds of success based on history, etc....

scarlet1967 wrote: I was asked on Stocktwits from a share holder whether the company reverse fibrosis or not?
Shareholder there are asking what NASH means?
Shareholders there ask where they can find company's investor presentation on the website and when the find it they can't understand it?
Other comparable companies have much higher followers on Twitter, Stocktwits, yahoo finance chat sector and even on this MB!
The company is definitely unknown and certainly not understood.

 

 




<< Previous
Bullboard Posts
Next >>

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse